Blindness gene therapy price tag stirs controversy – ModernMedicine
|
Blindness gene therapy price tag stirs controversy
ModernMedicine "Our own non-traditional distribution model—offering access through either Accredo or CuraScript—which we have leveraged successfully with other high cost therapies such as Spinraza, reduces the risk providers and hospitals have in keeping expensive … |
